Result: Risk Minimisation Materials for medicines starting with the letter C

Cablivi

Genzyme Therapeutics

Cablivi 10 mg powder and solvent for solution for injection – Patient Card - Risk Minimisation Information for Patients

Cablivi is subject to additional monitoring. This will allow quick identification of new safety information. If you notice any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the Patient Information Leaflet. For hard copies please contact our medical information department at 0845 372 7101 or email [email protected]

Cablivi 10 mg powder and solvent for solution for injection- Healthcare Professional Letter- Risk Minimisation Information for Healthcare Professionals

Sanofi Genzyme is required to distribute copies of the approved risk minimisation educational material for Cablivi ® (caplacizumab) to relevant healthcare professionals. Caplacizumab, the active ingredient of Cablivi, is a humanised bivalent Nanobody targeting the A1 domain of von Willebrand factor. For hard copies please contact our medical information department at 0845 372 7101 or email [email protected]

For Healthcare Professionals

Capexion

Generics UK T/A Mylan

Patient Card for Tacrolimus

Patient card for Tacrolimus

Caprelsa

Genzyme Therapeutics

Caprelsa ( Vandetanib) – Patient Card - Risk Minimisation Information for Patients

This medicine is subject to additional monitoring. This will allow quick identication of new safety information. You can help by reporting any side effects you may get. In the UK see www.mhra.gov.uk/yellowcard for how to report side effects

Caprelsa (Vandetanib) - Patient Guide - Risk Minimisation Information for Patients

The guide should be provided to patients prior to treatment by the prescribing physician and includes a description of the risks of treatment, guidance on what to do in the event of risks occurring including your doctors contact details and an overview of treatment monitoring

Caprelsa (Vandetanib) - Risk minimisation HCP Guide

For hard copies please contact our medical information department at 0845 372 7101 or email [email protected]

For Healthcare Professionals

Caprelsa (Vandetanib) -Healthcare Professional Letter

For hard copies please contact our medical information department at 0845 372 7101 or email [email protected]

For Healthcare Professionals

Carbimazole

ADVANZ Pharma

Carbimazole or thiamazole* (synonym: methimazole)-containing products: risk of acute pancreatitis and strengthened advice on contraception

Carbimazole or thiamazole* (synonym: methimazole)-containing products: (1) risk of acute pancreatitis and (2) strengthened advice on contraception

For Healthcare Professionals

Cellcept

Roche Products Limited

CellCept: Guide for Healthcare Professionals

This material is provided by Roche Products Ltd and forms part of the licence requirement. Please ensure that you are familiar with this material as it contains important safety information

For Healthcare Professionals

CellCept: Guide for Patients

This material is provided by Roche Products Ltd as a licence requirement. Please ensure that you are familiar with this material as it contains important safety information.

Cerdelga

Genzyme Therapeutics

CERDELGA (eliglustat) Prescriber Guide

For hard copies please contact our medical information department at 0845 372 7101 or email [email protected] .

For Healthcare Professionals

CERDELGA (eliglustat) Patient Alert card

For hard copies please contact our medical information department at 0845 372 7101 or email [email protected] .

Cerdelga® (eliglustat) Healthcare Professional Letter

For hard copies please contact our medical information department at 0845 372 7101 or email [email protected]

For Healthcare Professionals

Cerezyme

Genzyme Therapeutics

Cerezyme (imiglucerase) - Home Infusion HCP Manual - Risk Minimisation Information for Healthcare Professionals

The objective of this document is to provide guidance to healthcare professionals for the management of patients receiving Cerezyme (imiglucerase) at home.

For Healthcare Professionals

Cerezyme (imiglucerase) - Home Infusion Patient Manual - Risk Minimisation Information for Patients

The objective of this document is to provide patients with guidance on how to receive Cerezyme (imiglucerase) at home. It is the responsibility of the treating physician to supply this material to patients only if the treating physician decides that the patient is eligible for home infusion treatment.

Cilest

Janssen-Cilag Ltd

Annex 2 Checklist for Prescribers

Checklist for prescribers to guide them on discussion with patients on risk factors associated with Combined hormonal contracpetives and thromboembolism

For Healthcare Professionals

Annex 3 Important Information for Women

Document summarises important risk factors of a blood clot and advises on action to be taken if certain symptoms are experienced

Annex 4 leaflet for women

Leaflet with information on combined oral contraception to be given to patient by the physician

Cimzia

UCB Pharma Limited

Cimzia Patient Alert card

This alert card contains important safety information that patients need to be aware of before they are given CIMZIA and during treatment with CIMZIA.

Cinryze

Shire Pharmaceuticals Limited

Cinryze - Risk Management Plan Letter

Letter sent to HCPs informing them of the updated educational materials and website for the reconstitution and administraiton of Cinryze

For Healthcare Professionals

Cinryze Patient Diary

This Patient Diary is intended for patients to use to record the date, lot numbers, and reason for injection each time they inject Cinryze (C1 esterase inhibitor [human]) so that they can share this information with their treating physician at their next visit.

Cinryze Reconstitution and Administration Instructions for Healthcare Professionals

This Healthcare Professional Guide provides instruction on the procedures for the reconstitution and administration of Cinryze (C1 inhibitor [human]).

For Healthcare Professionals

Instructions for Patients and Caregivers on the Preparation and Administration of Cinryze

This Guide is intended for Patients and Caregivers to provide instruction on the preparation and administration of Cinryze

Ciprofloxacin

Generics UK T/A Mylan

Direct HCP Communication: Systemic and inhaled fluoroquinolones: risk of aortic aneruysm and dissection

Direct HCP Communication: Systemic and inhaled fluoroquinolones: risk of aortic aneruysm and dissection

For Healthcare Professionals

Cleosensa

Accord-UK Ltd

CHCs Annex 1 Direct HCP Communication

Direct Healthcare Professional Communication, to inform of the results of a Europe-wide review and the latest evidence on the risk of thromboembolism in association with certain combined hormonal contraceptives (CHCs).

For Healthcare Professionals

CHCs Annex 2 Checklist for Prescribers

Combined Hormonal Contraceptives - checklist for prescribers.

For Healthcare Professionals

CHCs Annex 3 Risk of blood clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

CHCs Annex 4 Important Information for women

Combined hormonal contraceptives - important information for women.

Clexane

SANOFI

Clexane®- Temporary UK supply shortage

For Hard copies of this information booklet please contact Sanofi medical information department on 0845 372 7101 or email [email protected]

For Healthcare Professionals

Temporary UK supply shortage of Clexane® (enoxaparin sodium) Syringes 4,000 IU (40 mg)/0.4 ml solution for injection in pre-filled syringes

For hard copies please contact our medical information department at 0845 372 7101 or email [email protected] .

For Healthcare Professionals

Co-cyprindiol

Fannin (UK) Ltd

Co-Cyprindiol Patient Card UK

Co-Cyprindiol Patient Card UK

Co-Cyprindiol Prescriber Checklist UK

Co-Cyprindiol Prescriber Checklist UK

For Healthcare Professionals

Colobreathe

Teva UK Limited

Colistimethate Sodium - (Colobreathe) HCP User Guide

In this booklet, you will find detailed information on how to load the Colobreathe Turbospin inhaler, patients should inhale the medicine and inspect and clean the device.

For Healthcare Professionals

Colistimethate Sodium - (Colobreathe) Patient User Guide

In this booklet, you will find detailed information on how to load the Colobreathe Turbospin inhaler, how to inhale the medicine and inspect and clean the device.

Concerta

Janssen-Cilag Ltd

Physician's guide to prescribing website

Website to host materials for physicians to support appropriate prescribing of methylphenidate

For Healthcare Professionals

Cubicin

Merck Sharp & Dohme Limited

Cubicin (daptomycin): Important safety information to minimise the risk of myotoxicity and dysregulation of in vivo coagulation- Dosage Card for Physicians

Under the Cubicin Marketing Authorisation, MSD are required to ensure that all HCPs likely to treat patients with daptomycin are provided with risk minimisation materials. This document contains key information to help minimize the risks of myotoxicity and dysregulation of in vivo coagulation. It also provides dosage recommendations and calculates the dose of daptomycin 50 mg/ml solution that is required from the weight of the patient. The licensed indications have been extended to include paediatric patients with S. aureus bacteraemia associated with cSSTI aged from 1 to 17 years of age. The document has been updated to include information on use in this population. If you require further information and hard copies of the material please contact [email protected] If you have any questions or require additional information, please call MSD Medical Information Services on 01992 467272.

For Healthcare Professionals

Cubicin (daptomycin): Important safety information to minimise the risk of reduced susceptibility of S.aureus to daptomycin- The Laboratory Susceptibility Testing Leaflet

As part of the terms of the Marketing Authorisation for Cubicin, MSD are required to ensure that all Healthcare Professionals who are likely to treat patients with daptomycin are provided with risk minimisation materials. This document contains key information to help minimise the risk of reduced susceptibility of S.aureus to daptomycin. It also provides a detailed explanation of the susceptibility testing issues, including the need for calcium in the testing medium. The leaflet has been updated as follows: •Deletion of the reason why the BBL™ Mueller-Hinton test method is recommended in the E test section •Throughout the text, the range fort the Ca2+ concentration has also been displayed in ‘mmol/L’ •References updated If you require further information about daptomycin and hard copies of the material please contact [email protected] If you have any questions or require additional information, please call MSD Medical Information Services on 01992 467272.

For Healthcare Professionals

cynril

Fontus Health Ltd

Cynril Patient Diary

This Patient Diary is designed to help you monitor your experience of BTcP and your use of Cynril. It will give you and your doctor a valuable insight into your progress and ensure you are receiving the correct level of treatment.

Cynril Patient Guide

Patient Guide For Cynril (fentanyl citrate) Lozenges

Cynril Prescription Guide for HCP

The prescription guide is designed to provide information around the use of Cynril (fentanyl citrate) lozenges for Healthcare Professionals (HCPs). More specifically, identifying appropriate patients and correctly prescribing Cynril to minimise the risk of misuse/pharmacodependence, abuse, medication errors, drug diversion, accidental exposure, overdose, off-label use, respiratory depression and local tolerability (dental decay) in patients not receiving opioid background therapy.

For Healthcare Professionals